Press Releases

BASEL, Switzerland, June 29, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announces it has closed each of its previously announced public offering of ...

Combined Gross Proceeds from Public Offering and Private Sale Total $50 Million BASEL, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare ...

BASEL, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the launch of a follow-on public offering of its ordinary ...

BASEL, Switzerland, June 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today published the invitation to the 2022 Annual General Meeting, which will ...

– Interim proof-of-concept data anticipated from STARGAZE in H1 2023 – First-in-class regenerative, non-immunosuppressive approach to treating acute Graft-versus-Host Disease – Second clinical indication under evaluation for apraglutide, demonstrating broad potential of this next generation GLP-2 ...

BASEL, Switzerland, May 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive ...

Arena Pharmaceuticals and Actelion veteran brings deep industry experience as VectivBio prepares for key upcoming catalysts BASEL, Switzerland, April 21, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel ...

Significant Progress Across Multiple Programs with Key Upcoming Catalysts Beginning H2 2022 STARS Phase 3 Program of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) On-Track for Topline Results at End of 2023 Cash Runway Extends Beyond Anticipated Release of Topline STARS Phase ...

Exclusive License with Asahi Kasei Pharma to develop and commercialize Apraglutide in Japan includes $30 million upfront cash payment, eligibility for up to $170 million in development and commercial milestones and double-digit royalties on apraglutide sales in Japan Loan facility established with ...

-- Apraglutide well-tolerated and does not require dose-adjustment in patients with severe renal disease -- -- Results demonstrate potential to reach 28% of SBS-IF patients with renal dysfunction who are underserved by currently available therapies -- BASEL, Switzerland, March 29, 2022 (GLOBE ...